Shiou-Hwei YehDING-SHINN CHENPEI-JER CHEN2021-07-032021-07-0320030305-7453https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984549350&doi=10.1093%2fjac%2fdkg326&partnerID=40&md5=b0560d512cc1fe749528bb5bbc4242achttps://scholars.lib.ntu.edu.tw/handle/123456789/568754Antivirals; Genetic polymorphism; Hepatitis virus[SDGs]SDG3adefovir dipivoxil; adenosine deaminase; alanine aminotransferase; alpha interferon; antivirus agent; gamma interferon; guanosine triphosphatase; initiation factor 2; interferon; interleukin 10; Janus kinase; lamivudine; major histocompatibility antigen class 1; major histocompatibility antigen class 2; mannose binding protein; nitric oxide synthase; nuclease; nucleoside analog; nucleotide derivative; ribavirin; ribonuclease; STAT protein; tumor necrosis factor alpha; virus DNA; virus RNA; antiviral activity; apoptosis; article; cellular immunity; chronic hepatitis; disease course; drug sensitivity; genetic polymorphism; genetic variability; genotype; haplotype; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; host resistance; human; immune response; immunotherapy; liver cell carcinoma; liver cirrhosis; nonhuman; pharmacogenomics; promoter region; single nucleotide polymorphism; treatment outcome; treatment planning; virus genome; virus hepatitis; virus load; virus replication; virus virulencejournal article10.1093/jac/dkg326128377272-s2.0-84984549350